Pfizer and BioNTech sought first COVID-19 vaccine approval in the United States.
Pharmaceuticals companies Pfizer and BioNTech on Friday had sought an approval to release their jointly-developed COVID-19 vaccine early in the United States as a first step towards relief.
This, as the increasing number of coronavirus infections prompted a return to shutdowns that traumatized nations and the global economy earlier this year.
The world was looking to scientists for salvation from the global coronavirus pandemic as a new wave of COVID-19 infections forced New York to close schools and California to impose night time curfews.
The Food and Drug Administration in the United States (US FDA) said that its vaccines committee would meet on December 10 in order to tackle the request for emergency use authorization (EUA).
In a statement, US FDA Commissioner Stephen Hahn said that the FDA recognized that transparency and dialogue were critical for the public to have confidence in coronavirus vaccines.
Hanh also wanted to assure Americans that the FDA’s process and evaluation of the data for a potential coronavirus vaccine would be as open and transparent as possible.
He also said that he couldn’t predict how long the review will take, but the federal government earlier said that the final approval would probably come in December.
“Filing in the US represents a critical milestone in our journey to deliver a COVID-19 vaccine to the world,” Pfizer chief executive Albert Bourla said.
Pfizer and BioNTech’s jointly-developed COVID-19 vaccine and Moderna’s COVID-19 vaccine had taken the lead in the global chase for COVID-19 vaccine.